Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

por Fervenza, Fernando C, Torra, Roser, Warnock, David G
Publicado 2008

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease

por Nikolaenko, Valeria, Warnock, David G, Mills, Kevin, Heywood, Wendy E
Publicado 2023

Current and Investigational Therapeutics for Fabry Disease

por Felis, Andrew, Whitlow, Michael, Kraus, Abigayle, Warnock, David G., Wallace, Eric
Publicado 2019

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease

por Nowak, Albina, Beuschlein, Felix, Sivasubramaniam, Visnuka, Kasper, David, Warnock, David G
Publicado 2022

Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis

por Powell, T Clark, Powell, Stephen L, Allen, Bryant K, Griffin, Russell L, Warnock, David G, Wang, Henry E
Publicado 2014

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study

por Wanner, Christoph, Kimonis, Virginia, Politei, Juan, Warnock, David G., Üçeyler, Nurcan, Frey, Aline, Cornelisse, Peter, Hughes, Derralyn
Publicado 2022

Fibrosis: a key feature of Fabry disease with potential therapeutic implications

por Weidemann, Frank, Sanchez-Niño, Maria D, Politei, Juan, Oliveira, João-Paulo, Wanner, Christoph, Warnock, David G, Ortiz, Alberto
Publicado 2013

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

por Mehta, Ravindra L, Kellum, John A, Shah, Sudhir V, Molitoris, Bruce A, Ronco, Claudio, Warnock, David G, Levin, Adeera
Publicado 2007

The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old

por Colantonio, Lisandro D., Tanner, Rikki M., Warnock, David G., Gutiérrez, Orlando M., Judd, Suzanne, Muntner, Paul, Bowling, C. Barrett
Publicado 2016

Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease

por Nguyen Dinh Cat, Aurelie, Escoubet, Brigitte, Agrapart, Vincent, Griol-Charhbili, Violaine, Schoeb, Trenton, Feng, Wenguang, Jaimes, Edgar, Warnock, David G., Jaisser, Frederic
Publicado 2012

Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice

por Nelson, Michael P, Tse, Tonia E, O’Quinn, Darrel B, Percival, Stefanie M, Jaimes, Edgar A, Warnock, David G, Shacka, John J
Publicado 2014

Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan

por Schoolwerth, Anton C, Engelgau, Michael M, Rufo, Kathy H, Vinicor, Frank, Hostetter, Thomas H, Chianchiano, Dolph, McClellan, William M, Warnock, David G
Publicado 2006

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

por Schiffmann, Raphael, Warnock, David G., Banikazemi, Maryam, Bultas, Jan, Linthorst, Gabor E., Packman, Seymour, Sorensen, Sven Asger, Wilcox, William R., Desnick, Robert J.
Publicado 2009

High-Sensitivity C-Reactive Protein and Risk of Sepsis

por Wang, Henry E., Shapiro, Nathan I., Safford, Monika M., Griffin, Russell, Judd, Suzanne, Rodgers, Joel B., Warnock, David G., Cushman, Mary, Howard, George
Publicado 2013

Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: the REasons for Geographic and Racial Differences in Stroke (...

por Plantinga, Laura, Howard, Virginia J, Judd, Suzanne, Muntner, Paul, Tanner, Rikki, Rizk, Dana, Lackland, Daniel T, Warnock, David G, Howard, George, McClellan, William M
Publicado 2013

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

por Warnock, David G, Thomas, Christie P, Vujkovac, Bojan, Campbell, Ruth C, Charrow, Joel, Laney, Dawn A, Jackson, Leslie L, Wilcox, William R, Wanner, Christoph
Publicado 2015

Obesity, metabolic health, and the risk of end-stage renal disease

por Panwar, Bhupesh, Hanks, Lynae J., Tanner, Rikki M., Muntner, Paul, Kramer, Holly, McClellan, William M., Warnock, David G., Judd, Suzanne E., Gutiérrez, Orlando M.
Publicado 2014

Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study

por Dubin, Ruth F., Judd, Suzanne, Scherzer, Rebecca, Shlipak, Michael, Warnock, David G., Cushman, Mary, Sarnak, Mark, Parikh, Chirag, Bennett, Michael, Powe, Neil, Peralta, Carmen A.
Publicado 2018

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy

por Nakano, Sachie, Tsukimura, Takahiro, Togawa, Tadayasu, Ohashi, Toya, Kobayashi, Masahisa, Takayama, Katsuyoshi, Kobayashi, Yukuharu, Abiko, Hiroshi, Satou, Masatsugu, Nakahata, Tohru, Warnock, David G., Sakuraba, Hitoshi, Shibasaki, Futoshi
Publicado 2015

Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease...

por Germain, Dominique P, Oliveira, João Paulo, Bichet, Daniel G, Yoo, Han-Wook, Hopkin, Robert J, Lemay, Roberta, Politei, Juan, Wanner, Christoph, Wilcox, William R, Warnock, David G
Publicado 2020